Cargando…

Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer

CONTEXT: Second‐generation androgen receptor inhibitors (ARIs) extend metastasis‐free survival, prolong overall survival, and delay symptoms when added to androgen deprivation therapy for the treatment of castration‐sensitive or castration‐resistant prostate cancer (CRPC). However, ARIs may adversel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beer, Tomasz M., Shore, Neal, Morgans, Alicia, Winters‐Stone, Kerri, Wefel, Jeffrey S., George, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	To the Journals
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579880/ https://www.ncbi.nlm.nih.gov/pubmed/36267196 http://dx.doi.org/10.1002/bco2.179

Ejemplares similares

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

A review of prostate cancer treatment impact on the CNS and cognitive function
por: Ryan, Charles, et al.
Publicado: (2019)

Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
por: Wefel, Jeffrey S., et al.
Publicado: (2022)

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance
por: Huang, Phoebe A., et al.
Publicado: (2018)

Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
por: Holder, S L, et al.
Publicado: (2015)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Perpetuating Effects of Androgen Deficiency on Insulin-resistance
por: Cameron, Judy L., et al.
Publicado: (2016)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
por: Lallous, Nada, et al.
Publicado: (2013)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
por: Sonnenburg, Daniel, et al.
Publicado: (2018)

An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
por: Morgans, Alicia K., et al.
Publicado: (2022)

The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison
por: Shore, Neal, et al.
Publicado: (2022)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
por: Leaning, Darren, et al.
Publicado: (2023)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
por: Gunter, Jennifer H., et al.
Publicado: (2012)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
por: Zadra, Giorgia, et al.
Publicado: (2019)

Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2017)

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting
por: Sawant, Mithila, et al.
Publicado: (2022)

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
por: Shore, Neal D., et al.
Publicado: (2020)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
por: Montgomery, Bruce, et al.
Publicado: (2010)

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer
por: Hung, Chiu-Lien, et al.
Publicado: (2023)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors
por: Ben-Eltriki, Mohamed, et al.
Publicado: (2018)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_il86d2f4lf9s4npkg64vbo63ve